VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NUTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NUTXNutex Health, Inc.
$174.51$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksNUTXCash Flow

Nutex Health, Inc. (NUTX) Cash Flow Statement

13Y historyFree accessUpdated daily

Operating cash flow of $78.3M converted to free cash flow of $77.1M in 2026Q3 (a 35.5% FCF margin), yet quarterly FCF margins ranging from -0.1% to 45.5% and $53.7M in dividends paid suggest cash generation is episodic and may be outpacing sustainable capital returns.

Income StatementBalance SheetCash FlowRatios

NUTX Cash Flow Statement

Annual statement

NUTX Cash Flow Statement

Nutex Health, Inc. (NUTX) cash flow statement — 13-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'11Dec'10
Cash from Operations258.45M248.13M23.15M1.26M50.61M173.43M86.67M12.12M-480.05K-714.62K-274.22K44.91K-664.57K-889.1K
Operating CF Margin %-28.35%4.82%0.51%23.08%52.31%31.63%12.49%-35.12%-3084.79%---26.08%-70.21%
Operating CF Growth %52.38%971.64%1742.79%-97.52%-70.82%100.1%614.84%2625.71%32.82%-160.6%-710.65%106.76%25.25%-
Net Income164.71M180.36M95.27M-43.42M-432.74M168.53M145.56M32.09M-950.13K582.06K-451.06K-536.13K-383.39K158.14K
Depreciation & Amortization21.62M20.53M18.97M17.59M13.13M7.66M5.9M2.48M522535.02K4736625.92K1.5K
Stock-Based Compensation6.36M117M16.63M2.84M189.58K000208.03K924.33K008155.83K
Deferred Taxes-4.16M17.08M-13.13M-5.71M5M0000-115.22K00-184.19K-161.39K
Other Non-Cash Items-49.94M902K9.81M31.62M400.71M-5.51M1.24M-596.94K-49.45K-2.83M-130.63K563.79K104.01K-1.05M
Working Capital Changes56.32M-87.74M-104.4M-1.66M64.32M2.75M-66.02M-21.85M310.99K193.65K307K-116.58K-207.73K161.39K
Change in Receivables44.76M-89.32M-173.41M-4.58M58.08M-6.62M-71.23M-24.74M-82.09K-4K056.7K-144.7K-67.91K
Change in Inventory-1.99M-16K540.77K142.7K-719.11K-1.09M-825.77K-486.27K12700000
Change in Payables-5.72M37.85M-10.72M-2.25M9.69M6.27M6.23M1.63M402.25K119.22K187.03K77.79K-63.03K229.3K
Cash from Investing-14.02M-5.24M-2.67M-11.24M-4.34M-36.98M-61.19M-31.23M-116.96K2.05K-9.99K1.83K18.1K-477.69K
Capital Expenditures-6.35M-2.53M-2.3M-9.5M-14.63M-36.93M-61.19M-32.28M0000-19.39K-5.69K
CapEx % of Revenue0.8%0.29%0.48%3.83%6.67%11.14%22.33%33.25%-0.01%--0.76%0.45%
Acquisitions1.99M0-361.32K-1.74M10.3M-48.85K01.04M-116.96K-30.8K0000
Investments--------------
Other Investing-8.31M-4.31M000000032.85K-9.99K1.83K37.49K-472K
Cash from Financing-157.22M-97.95M1.09M-2.27M-48.13M-125.85M-7.97M21.71M704.57K711.5K172.44K-51.28K022.89K
Debt Issued (Net)-18.15M-19.44M-7.4M2.65M-5.59M-3.22M41.27M35.57M337.27K461K48.47K000
Equity Issued (Net)-56.68M-5M9.2M04.76M0120K00275K0000
Dividends Paid-82.33M-74.28M-6.44M-5.21M-51.23M-144.34M-59.05M-18.9M000000
Share Repurchases-55.69M-5M000000000000
Other Financing-67K767K5.73M298.03K3.93M21.71M9.69M5.05M367.3K-24.5K123.98K-51.28K022.89K
Net Change in Cash87.51M145.23M21.58M-12.25M-1.86M10.6M17.51M2.6M109.82K-1.07K-111.77K-4.54K-240.75K-391.52K
Free Cash Flow252.1M245.6M20.85M-8.24M35.97M136.51M25.48M-20.15M-480.05K-714.62K-274.22K44.91K-683.97K-894.79K
FCF Margin %31.65%28.06%4.34%-3.33%16.4%41.17%9.3%-20.76%-35.12%-3084.79%---26.84%-70.66%
FCF Growth %43.02%1077.94%353.02%-122.91%-73.65%435.67%226.46%-4097.63%32.82%-160.6%-710.65%106.57%23.56%-
FCF per Share35.8036.354.09-1.878.5034.545.94-4.87-0.07-0.17-0.130.02-0.57-0.75
FCF Conversion (FCF/Net Income)1.53x3.51x0.44x-0.03x-0.12x1.31x0.82x0.58x0.17x-1.23x0.04x0.54x1.73x-5.62x
Interest Paid17.98M2.51M3.47M1.64M4.62M4.1M3.25M427.4K000000
Taxes Paid44.53M72.81M798.99K849.36K8.23M335.34K181.34K0000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Cash conversion volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Quality Swings With Cash Timing

According to reported quarterly figures, Nutex converted net income into operating cash flow at 1.95x in 2026Q3 and 0.52x in 2026Q2, a dispersion that suggests headline earnings are not a stable guide to cash generation across quarters.

The gap between net income and operating cash flow is the central signal here, and it swings in both directions, including negative operating cash flow in 2024Q4 despite $61.7M of reported net income. Working capital movements of roughly $50M to $100M per quarter appear to be doing much of the reconciling work, which may indicate that collections timing or claims accruals, rather than underlying profitability, are driving reported earnings. Investors should monitor whether conversion normalizes toward 1.0x over a full year, since persistent divergence would warrant further investigation into receivables quality.

Free Cash Flow Lumpy Rather Than Trending

Based on Nutex's reported figures, free cash flow margin moved from 35.5% in 2026Q3 to 15.0% in 2026Q2 and from -0.1% to 45.5% across adjacent quarters, a pattern that suggests cash generation is episodic rather than trend-driven.

Capital expenditure is minimal, running well below 1.5% of revenue in every period, so free cash flow essentially tracks operating cash flow and inherits its volatility. The absence of a steady FCF trajectory limits confidence in using recent quarters as a run-rate base. The stronger 2026 readings appear tied to working capital release rather than a demonstrable improvement in recurring cash earnings.

Working Capital Drives Quarterly Cash Swings

As reported in the quarterly cash flow statements, working capital changes ranged from a $108.6M drag in 2024Q4 to a $56.9M release in 2025Q4, indicating that receivables and claims timing dominate reported operating cash flow.

These magnitudes are large relative to quarterly operating cash flow, which suggests the cash profile depends heavily on the timing of collections from payers. The reported data does not break out receivables, inventory, or payables, so the specific driver cannot be confirmed from these figures. Management's collection performance warrants closer scrutiny, particularly given the provision for doubtful accounts typical of emergency-care operators.

Buybacks and Dividends Absorb Recent Inflows

According to the reported cash flow data, Nutex returned $53.7M through dividends in 2026Q3 and $31.7M through buybacks in 2026Q1, deploying cash in a way that appears to follow strong collection quarters.

Capital returns appear to be timed to periods of elevated operating cash flow, which may reflect a policy of distributing windfall collections rather than a fixed payout framework. Acquisition outflows are small and sporadic, suggesting the company is not currently relying on purchased growth to sustain its revenue trajectory. Whether these distributions remain affordable depends on whether the cash conversion pattern proves durable, which the data does not yet establish.

Stock-Based Compensation Flatters Reported Cash

Based on reported figures, stock-based compensation ranged from $2.0M to $78.7M per quarter, and in 2025Q2 it exceeded the entire operating cash flow of $27.3M, suggesting cash flow may be overstated relative to economic cost.

Because SBC is a non-cash add-back, quarters with large SBC inflate the operating cash flow line relative to economic earnings, which may obscure the true cost of employee compensation. The 2025Q2 spike and the negative 2026Q1 SBC entry both warrant further investigation into the accounting treatment. Investors should examine whether SBC levels are sustainable and how they are reconciled against the cash-based view of profitability.

NUTX — Frequently Asked Questions

Quick answers to the most common questions about buying NUTX stock.

How much cash does Nutex Health, Inc. (NUTX) generate from operations?

Nutex Health, Inc. (NUTX) generated $248.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Nutex Health, Inc.'s free cash flow?

Nutex Health, Inc. (NUTX) generated $245.6M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Nutex Health, Inc.'s capital expenditure (CapEx)?

Nutex Health, Inc. (NUTX) spent $2.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Nutex Health, Inc. distribute cash to shareholders?

In 2025, Nutex Health, Inc. (NUTX) returned $74.3M to shareholders via cash dividends and spent $5.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.